IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection - Wikidata - wikimedia - TriplyDB

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

http://www.wikidata.org/entity/Q28276247

about

Lack of response to exogenous interferon-α in the liver of chimpanzees chronically infected with hepatitis C virus Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4 Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV Anti-HDV IgM as a marker of disease activity in hepatitis delta Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Serum inflammatory mediators as markers of human Lyme disease activity.Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.Profiles of acute cytokine and antibody responses in patients infected with avian influenza A H7N9 A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.In vitro blood cell responsiveness to IFN-α predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients.Chemokines in the immunopathogenesis of hepatitis C infection Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.Lethal Nipah virus infection induces rapid overexpression of CXCL10.HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C Chemokine antagonism in chronic hepatitis C virus infection Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness.Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients.Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature.Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients.Effects of low-level laser therapy on M1-related cytokine expression in monocytes via histone modification.CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.Clinical implications of chemokines in acute and chronic hepatitis C virus infection.Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation

P2860

Q27486088-C017F173-F7CB-4FB9-AB59-9819A42C29EB Q27490393-0C314103-EB00-4F43-A96D-EE75906DB80C Q27490866-C82EBDFA-264A-4B39-B336-E13FB45EF7A7 Q28274298-B284CE12-977D-4339-B89F-7FC3968B06AF Q28287283-7D115C43-EACA-4556-9D1D-DAF504007306 Q28541284-BD0D86EE-6D25-464B-8CAA-0CD7712C7DF7 Q29615959-1E2E904E-5CF2-4C18-9F18-CAFB66B68DA5 Q31158874-C9FF49E7-5F9C-4720-9905-D7860606F309 Q33365130-77CA63C3-FEC4-4A6A-BFC9-49A29B4C1AB6 Q33597579-0406C4B8-D142-4FD9-843F-23061E378349 Q33706737-A8B28E19-BF65-4268-8F89-218A37E35D6E Q33745372-E5D07A25-63FC-4DCA-8EEA-F42A6555C896 Q33797446-F11E566E-7752-48C9-9018-49BDC21F3BC1 Q33816657-0579463F-F681-4A93-880E-A07AF16A8454 Q33842239-2D22D0C2-DAAF-4C39-8636-B2A79EDAEDC9 Q33864111-2DBE7FE0-3D32-4D5B-BEF3-5D8F5876F790 Q33906899-38429A52-848C-4C17-B65B-642A736E73BA Q33958609-1D158FE6-8A96-4968-A0CF-6A8CDD369523 Q34056271-7DB474AA-8F64-4D27-95E5-E53239BFC5E7 Q34087387-FCF4DFBF-71E0-4341-AE3A-127C43E5932A Q34185782-44D873D0-63CD-4F2E-A313-98AB9DC117CB Q34247460-C5820035-6850-4200-8C9C-1D236AF237C0 Q34335634-046EFB82-6F3F-492A-BF28-1E698214D6D1 Q34429056-843D001C-DD1C-400C-820E-492FB6D3A7D7 Q34477691-A6463B76-355F-41B0-B14F-721320EA3CF5 Q34599847-A5270EB3-D9B8-469F-B57D-A52B80AB66FE Q34769512-848563FA-DDDC-4F36-A1E3-3F2624D44460 Q34867045-ADA4CE0B-9416-4A89-B230-0F3990CAF323 Q34984063-0C766D56-5B54-40FA-945E-6A4DE333DD6E Q35017075-0D0D08F6-5C13-4C38-B631-77EEFFCA3856 Q35018680-554987B3-D4D3-435C-8F7F-A308087A29F2 Q35047686-4356D05B-ACF7-4347-B4A2-8D0B05317175 Q35053399-47C370AA-8767-446B-B3F9-D727F1343716 Q35065912-8FFFF00F-B671-48B7-8614-8442A35ED6FA Q35077995-B75394CC-7389-4ADD-BF34-99365ED5C8FA Q35137871-E83C3DBC-DC60-4AF4-9E6A-D9158DF60F68 Q35469531-BC85AD11-ABAA-4D86-8363-C8C0C788C9FB Q35561908-EAD2C097-0D67-471F-BD92-E71196B732AD Q35640461-81913479-5224-4AC2-BEBA-13367F071D91 Q35680404-06906E7E-0148-4BAA-B598-0A05B861BDC6

P2860

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

http://www.wikidata.org/entity/Q28276247

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

IP-10 predicts viral response ...... with HCV genotype 1 infection

@ast

IP-10 predicts viral response ...... with HCV genotype 1 infection

@en

IP-10 predicts viral response ...... with HCV genotype 1 infection

@nl

type

label

IP-10 predicts viral response ...... with HCV genotype 1 infection

@ast

IP-10 predicts viral response ...... with HCV genotype 1 infection

@en

IP-10 predicts viral response ...... with HCV genotype 1 infection

@nl

prefLabel

IP-10 predicts viral response ...... with HCV genotype 1 infection

@ast

IP-10 predicts viral response ...... with HCV genotype 1 infection

@en

IP-10 predicts viral response ...... with HCV genotype 1 infection

@nl

P1433

Q28276247-9070F314-3346-4ADD-AA67-B16D2B8B17CD

P1476

Q28276247-E65BF810-9599-435B-ADAA-562398EDA6BF

P2093

Q28276247-13AA377B-AE85-4B75-A592-2548679A064E

Q28276247-37484ECE-FC1B-4EFD-8C3D-6A4E972AF0D2

Q28276247-8C2DB5F1-3CBA-40CE-9818-3161B403FA82

Q28276247-9E351D6D-04F2-46CA-A8BF-98C14D318772

Q28276247-A1116A9F-7642-4BD5-A48E-65A39787C69E

Q28276247-AD6F7A13-9DF6-4026-B8EA-08E4BA794732

Q28276247-AF809227-553C-44FA-AE20-45AB8C20573F

Q28276247-D351CD19-D369-472D-873F-39B7DF627B5E

Q28276247-EBBE57C6-1EB9-4FAE-857A-C0E504A9C5CA

P2860

Q28276247-EAD8874D-726C-41E9-B880-F4EA064B073A

P304

Q28276247-F82D73A3-C376-40A2-8123-A14EC0F4B1C4

P31

Q28276247-1C3F621B-2CF4-4653-AF5E-C29CC32CB5CA

P3181

Q28276247-88637D76-7636-4FA9-BC87-222C52616086

P356

Q28276247-2B488E28-5D87-477C-80FA-85A42A283FC2

P407

Q28276247-B0D39C2E-BAD3-4D21-8A28-D78F4D4A0B87

P433

Q28276247-23EBE06F-7996-4861-B7A9-6AB39D6CCD12

P478

Q28276247-5BA1DB39-15C3-49F7-868E-A61EB4BCB734

P50

Q28276247-1AD7A35F-3055-4038-A5C6-C4006D82EDAA

Q28276247-2DD66D60-310B-4FF1-937E-56D3267B4983

Q28276247-5597555F-3FE8-4829-9F29-6D882B90D1A1

Q28276247-7DCA076B-6842-44ED-BB42-A1FFB9F0489C

Q28276247-888272FA-1E32-41FD-AD26-33B19B3CC8AA

Q28276247-8E737DD6-87A1-4996-840A-A896AED6846E

Q28276247-E7FF2009-BC00-4F52-8FD3-AB72EB1F3F79

Q28276247-EA2A55D5-83E4-4A62-B380-09EF04420866

P577

Q28276247-1E289E8B-77C7-4D46-A9ED-F881CF1880BB

P5875

Q28276247-F46C80D9-B26B-4614-8FA3-A692C5C91BE2

P698

Q28276247-88C71F4E-D667-45A6-845B-A68B6D764BCC

P921

Q28276247-8DDBE7BC-99A5-42B9-B37B-2013D3BC4E65

P3181

P356

P1433

P1476

IP-10 predicts viral response ...... with HCV genotype 1 infection

@en

P2093

Amar P Dhillon

http://www.w3.org/2001/XMLSchema#string

Ana I Romero

http://www.w3.org/2001/XMLSchema#string

Avidan U Neumann

http://www.w3.org/2001/XMLSchema#string

Elke Verheij-Hart

http://www.w3.org/2001/XMLSchema#string

Francesco Negro

http://www.w3.org/2001/XMLSchema#string

Gunnar Norkrans

http://www.w3.org/2001/XMLSchema#string

Johan Westin

http://www.w3.org/2001/XMLSchema#string

Michael von Wagner

http://www.w3.org/2001/XMLSchema#string

Solko W Schalm

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

P304

1617-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1726140

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/HEP.21407

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Michel Pawlotsky

Bart L. Haagmans

Gabriele Missale

Elke Verheij-Hart

Kristoffer Hellstrand

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6666066

http://www.w3.org/2001/XMLSchema#string

P698

17133471

http://www.w3.org/2001/XMLSchema#string

P921